UK to offer prostate cancer screening only to a few thousand high-risk men
The UK National Screening Committee (UK NSC) has delivered a comprehensive response to the long-debated question of prostate cancer screening. According to BBC Health's reporting, the committee recommends that prostate cancer screening be opened not to men of all age groups but only to a defined subgroup of high-risk men who carry the BRCA2 gene mutation and have a first-degree relative with a history of prostate or breast cancer. The committee's assessment brings to the foreground the 'false-positive cost' problem that health economists and oncologists have argued over for years.
The context for the decision matters. Prostate cancer is the second most common form of cancer in men in the United Kingdom and is responsible for around 12,000 deaths each year. UK NSC chair Professor Bob Steele told the BBC: 'A large proportion of men may carry a slow-growing form of cancer that will never threaten their lives. A broad-based screening would lead to unnecessary treatment of those cancers and to side effects.' The leading treatment side effects are urinary incontinence and erectile dysfunction, which can materially reduce men's quality of life.
To reach its conclusion the committee conducted an eight-month literature review that included engagement with Prostate Cancer UK. The central reference for the review was the fifteen-year follow-up data from the ERSPC study run across fifteen European countries. That data showed that broad PSA testing reduced prostate cancer deaths by about 20 percent, but also revealed that 17 of every 1,000 men screened had unnecessary biopsies and nine received surgery or radiotherapy for cancers that required no treatment.
The question of who counts as high-risk is at the centre of the decision. According to information carried by the BBC, the committee calculated that men with the BRCA2 mutation are three to five times more likely to develop prostate cancer than the population average. Men with Lynch syndrome are also included in the high-risk group; the estimated number of men who will fall into the category is about 7,500. How those men will enter the screening programme will be clarified by NHS England in the coming twelve months.
Criticism of the decision is led by a coalition of prostate cancer survivor groups. Andy Edwards, head of the Prostate Cancer Action group, told the BBC: 'If my family had not known that I carried BRCA2, I would never have been screened at age 50. The committee's approach gives men with no family history false reassurance.' Edwards asked that NHS expand family-history-based screening processes and that the PSA test be available as part of the standard general-practitioner consultation package after age 50.
Another dimension of the decision is the system-protection argument. The committee's cost-benefit analysis calculated that broad screening would add roughly £320 million a year to the NHS bill, and that the unnecessary treatment it generates would add a further £110 million. By contrast the targeted screening programme for the high-risk group is projected to cost about £18 million a year.
Global screening practice is varied. According to the international comparison the BBC reports, the US Preventive Services Task Force recommends that the PSA test be carried out for men aged 55-69 on a 'doctor-patient discussion' basis. In Germany an annual digital examination is included in insurance packages. Australia, like the UK, prefers targeted screening to broad screening. That variation reflects each country's health economy and population age profile.
Technological progress will shape future debates. Professor Hashim Ahmed of Imperial College London told the BBC that the multiparametric MRI scan developed in recent years can roughly halve the false-positive rate of PSA testing. Ahmed said: 'If we succeed in scaling MRI-based screening methods over the next five years, the UK NSC may need to revisit its position.'
The question the decision raises for individuals concerns what it means for men over 50 with no family history of prostate cancer. The NHS confirms that those men, if they develop symptoms, should consult their GP and will have access to the PSA test when warranted. At the same time, GPs are not encouraged to routinely propose PSA tests to asymptomatic men.
This article is not medical advice; please consult a registered medical professional for personal health decisions. The committee's final recommendation will now be submitted to the UK government's Department of Health and Social Care, which will issue its formal response within 90 days. If the department accepts the committee's recommendation, the targeted screening programme for the high-risk group is planned to start as a pilot in NHS England in early 2027.